{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Pulmonary function tests will be measured in sitting position; however, if necessary to undertake', 'the testing with the subject standing or in another position, this should be noted on the spirometry', 'report. For any subject, the position should be consistent throughout the study.', 'Three measurements fulfilling the ATS acceptability and repeatability criteria should be obtained', 'at every visit, if possible. The acceptability criteria must be applied before the repeatability', 'criteria. Unacceptable maneuvers must be discarded before applying the repeatability criteria. If a', 'subject fails to provide repeatable and/or acceptable maneuvers, an explanation should be', 'recorded.', 'The largest FEV1 and largest FVC should be recorded after the data are examined from all of the', 'acceptable curves, even if they do not come from the same curve. The FEF 25-75% should be', 'obtained from the single curve that meets the acceptability criteria and gives the largest sum of', 'FVC plus FEV1 (best test).', 'Automated best efforts, which combine FEV1 and FVC are not acceptable.', 'The spirometer must be calibrated following the principles of the ATS/ERS guidelines every day', 'that a study subject is seen and spirometry is carried out. The calibration records should be kept in', 'a reviewable log. It is preferred that the calibration equipment (ie, 3-liter syringe) that is used to', \"calibrate the spirometer be subjected to a validated calibration according to the manufacturer's\", 'specifications.', 'Further details on spirometry will be available in a separate operational manual provided to the', 'sites.', '9.2.2.1.2 Reversibility/Post-bronchodilator FEV1', 'Reversibility is defined as an increase in absolute FEV1 of 10% over the baseline value,', 'demonstrated within 30 minutes of bronchodilator administration.', 'At the screening test, reversibility is tested after the administration of 200 to 400 mcg (2 to', '4 puffs) of albuterol/salbutamol or 45 to 90 mcg of (2 to 4 puffs) levalbuterol/levosalbutamol', 'reliever medication from a primed MDI (up to 3 opportunities during the same visit are allowed', 'with a maximum of 12 puffs of reliever medication, if tolerated by the patient). Documented', 'reversibility or positive airway hyperresponsiveness to methacholine within 12 months prior to', 'Visit 1 is considered acceptable.', 'All reversibility tests will be administered after pulmonary function testing and after asthma', 'medications have been withheld for the appropriate intervals. Patients will receive the', 'albuterol/salbutamol or levalbuterol/levosalbutamol reliever medication as puff inhalations using', 'the respective MDI. Alternatively, and only if it is consistent with usual office practice (to be', 'documented), reversibility testing may be performed using inhalation of nebulized', 'albuterol/salbutamol or levalbuterol/levosalbutamol reliever medication.', 'The spirometry for measuring absolute FEV1 may be repeated several times within the 30 minutes', 'after administration of bronchodilator.', 'Property of the Sanofi Group - strictly confidential', 'Page 61', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Reversibility is an inclusion criterion, but if the subject does not meet this reversibility criterion at', 'Screening Visit 1, up to 2 additional assessments can be performed at any time between Screening', 'and Baseline Visit 2.', 'For post-bronchodilator FEV1 at remaining study visits following randomization, the measure', 'should follow the steps as that at screening test for reversibility validation except a maximum of', '4 puffs of reliever medication can be used. If other attempt for reversibility test was performed at', 'Baseline Visit 2, then the post-bronchodilator FEV1 will come from the result of this reversibility', 'test.', '9.2.2.2 Disease-specific, Daily Efficacy Assessments', '9.2.2.2.1 Electronic Diary/PEF meter', 'On a daily basis throughout the study, the patient uses an electronic diary/PEF meter to:', 'Measure morning and evening PEF.', 'Respond to the morning and evening asthma symptom scale questions.', 'Indicate the number of inhalations/day of salbutamol/albuterol or', 'levosalbutamol/levalbuterol for symptom relief.', 'Record the number of inhalations/day of background product used.', 'Record the number of nocturnal awakenings due to asthma symptoms requiring the use of', 'reliever medication.', 'Record oral steroids use for exacerbation event.', 'At Screening (Visit 1), patients and parent(s)/caregiver(s)/legal guardian(s) will be issued an', 'electronic diary/PEF meter. Parent(s)/caregiver(s)/legal guardian(s) will be instructed on the use', 'of the device, and written instructions on the use of the electronic PEF meter will be provided to', 'the parent(s)/caregiver(s)/legal guardian(s) In addition, the Investigator will instruct the', 'arent(s)/caregiver(s)/legal guardian(s) on how to record the following variables in the electronic', 'PEF meter:', 'AM PEF performed within 15 minutes after arising (between 5:30 AM and 11:59 AM) prior', 'to taking any albuterol/salbutamol or levalbuterol/levosalbutamol reliever medication)', 'PM PEF performed in the evening (between 5:30 PM and 11:59 PM) prior to taking any', 'albuterol/salbutamol or levalbuterol/levosalbutamol reliever medication)', 'Patient/Parent(s)/caregiver(s)/legal guardian(s) should try to withhold albuterol/salbutamol', 'or levalbuterol/levosalbutamol reliever medication for at least 6 hours before performing', 'the PEF measurements.', 'Three PEF efforts will be performed by the patient; all 3 values will be recorded by the', 'electronic PEF meter, and the highest value will be used for evaluation', 'Baseline AM PEF will be the mean AM measurement recorded for the 7 days prior to the first', 'dose of investigational product, and baseline PM PEF will be the mean PM measurement recorded', 'Property of the Sanofi Group - strictly confidential', 'Page 62', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}